News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales
Promising early results, potential approval by 2027, targeting $609M peak sales
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
$CRDL BIG SHORT SQUEEZE
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.
Cardiol had around $21 million in cash at the end of Q1
NASDAQ: $CRDL
Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.
The 12-month price target is $10
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
NASDAQ: $CRDL H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
NASDAQ: $CRDL Promising clinical progress: Ongoing Phase II trials for myocarditis and pericarditis, with major data expected November 2024
Time to Add $CRDL Big wave coming
NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million, with key trial results due in November 2024?
CRDL under $2
CRDL under $3
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
4
|
Posts (Total)
|
224
|
|
Created
|
10/14/19
|
Type
|
Free
|
| Moderators | |||
AI
